This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

Expanded access is currently available for this treatment.
Verified August 2016 by University of Colorado, Denver
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: August 22, 2013
Last updated: August 18, 2016
Last verified: August 2016
Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary practice. Triclabendazole is considered to be a second-line drug for parasites and is used when other preferred agents cannot be used because they are ineffective or because adverse reactions limit their use. Although Triclabendazole is widely used in developing countries for the treatment of parasites it is not approved by the FDA for this treatment in the US. It is currently being distributed in the US through a special arrangement with the FDA and the manufacturer on an individual patient approval basis. This arrangement requires that a single patient Investigational New Drug (IND) be obtained from FDA for each patient requiring Triclabendazole. Upon approval by FDA, the manufacturer (Novartis) will ship the drug directly to the prescribing physician.

Condition Intervention
Parasitic Disease Drug: Triclabendazole

Study Type: Expanded Access     What is Expanded Access?
Official Title: "Compassionate Use of Triclabendazole for the Treatment of Parasites" (Prior to FDA Approval; Expanded Access Program)

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Intervention Details:
    Drug: Triclabendazole
    Triclabendazole (10 mg/kg body-weight as a single dose).
    Other Name: Egaten

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients with a diagnosis of parasites whose resistance pattern has indicated resistance to first line agents and sensitivity to Triclabendazole or in whom an additional drug needs to be added to their regimen because of inadequate response to existing therapy.
  • Patients with a parasite that is sensitive to Triclabendazole and who have experienced an allergic or adverse reaction to other agents that prevent their use.
  • Patients with parasitic disease that has responded to treatment with first line drugs but who experienced allergic or adverse reactions to these agents that has prevented their continued use or who have experienced a relapse in their disease that necessitates the addition, or substitution, of second-line agents
  • Patients who do not qualify for a study using Triclabendazole or for whom a study does not exist and thus the patient would not otherwise have access to the drug

Exclusion Criteria:

  • Anyone whose parasitic disease can be adequately treated by other available medications.
  • Anyone who is allergic or who has had a severe adverse reaction to Triclabendazole in the past.
  • Pregnant Women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01931085

Contact: Marilyn Levi, MD 720-848-0817 MARILYN.LEVI@UCDENVER.EDU

Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Marilyn Levi, MD University of Colorado, Denver
  More Information

Responsible Party: University of Colorado, Denver Identifier: NCT01931085     History of Changes
Other Study ID Numbers: 11-1438
Study First Received: August 22, 2013
Last Updated: August 18, 2016

Additional relevant MeSH terms:
Parasitic Diseases
Antiparasitic Agents
Anti-Infective Agents processed this record on August 21, 2017